SHIP HEALTHCARE HOLDINGS (3360) FY2027 Q1 Earnings Report

Quick View

Executive Summary

Despite higher revenue and lower operating income, Ordinary Income and Net Income increased due to non-operating factors, warranting caution regarding the quality of earnings growth. Revenue was ¥1763.6B (+8.0% YoY), Operating Income was ¥27.8B (-5.7%), Ordinary Income was ¥33.8B (+9.2%), and Net Income was ¥20.6B (+4.0%). Expansion of the core Medical Supplies Business drove revenue growth; however, deterioration in the gross margin resulted in lower operating income, while non-operating income, including foreign exchange gains and equity-method investment gains, pushed up Ordinary Income.

Factors Affecting Results

【Revenue】Revenue was ¥1763.6B, representing growth of +8.0% YoY and approaching the high-single-digit growth range. The Medical Supplies Business, which accounts for 88.1% of revenue, led the expansion with growth of +8.1%, while Total Pack Produce also posted strong growth of +12.3%. Life Care, by contrast, saw a slight decline in revenue of -1.4%, while Dispensing Pharmacies remained relatively solid at +3.2%.

【Profit and Loss】Operating Income was ¥27.8B, a decrease of -5.7% YoY. The gross margin was 7.7%, deteriorating from the previous year, and the increase in cost of sales offset the benefits of higher revenue. The SG&A ratio improved from the previous year to 6.2%, indicating effective cost control, but this was insufficient to absorb the increase in costs. Non-operating income was supported by dividends received of ¥1.4B, foreign exchange gains of ¥0.7B, and equity-method investment gains/losses of ¥3.0B, among other items. Non-operating expenses declined due to factors including lower interest expenses, resulting in Ordinary Income increasing to ¥33.8B (+9.2%). Extraordinary income and losses were limited, consisting primarily of a ¥0.3B loss on the disposal of fixed assets, and Profit Before Tax was ¥33.6B. Due to a higher tax burden, including an increase in the effective tax rate, Net Income was limited to ¥20.6B (+4.0%). In conclusion, the results reflect higher revenue but lower operating income, while growth in Ordinary Income and Net Income was substantially supported by non-operating factors.

Segment Analysis

By segment, the core Medical Supplies Business overwhelmingly dominates in scale, with revenue of ¥1322.0B (+8.1%), but its Operating Income was ¥10.9B (-7.6%) and its margin was 0.8%, highlighting its low profitability relative to the company-wide average. Dispensing Pharmacies maintained the highest margin at 9.8% against revenue of ¥86.4B (+3.2%), but profit declined to ¥8.5B (-8.4%). Total Pack Produce achieved the highest growth rate, with revenue of ¥272.5B (+12.3%), but its margin remained limited at 1.7%. Life Care recorded a slight revenue decline to ¥91.3B (-1.4%), while Operating Income increased to ¥4.6B (+11.6%), making it the only segment to post profit growth. Overall, the decline in profitability at the large-scale Medical Supplies Business was the primary cause of the company-wide decline in Operating Income, while the higher-profitability Dispensing Pharmacies and Life Care businesses were not large enough to offset it.

Key Financial Indicators

【Profitability】The Operating Margin and Net Margin were both low at 1.6% and 1.2%, respectively. The gross margin of 7.7% deteriorated from the previous year, indicating a structure in which revenue growth is not readily translating into profit growth. ROE was extremely low at 1.4%. 【Cash Quality】Cash and deposits were substantial at ¥777.5B, but accounts receivable and notes receivable were also large at ¥1192.2B, suggesting that the length of the collection cycle may be affecting cash generation capacity. Inventories were ¥269.8B, an increase from the previous fiscal year, indicating that inventory accumulation tied up working capital. 【Investment Efficiency】Total assets were ¥3717.9B and net assets were ¥1481.5B. Total asset turnover, an indicator of asset efficiency, was low, highlighting a capital efficiency challenge in which substantial capital is being employed while profitability remains low. 【Financial Soundness】The Equity Ratio was 39.8%, a slight improvement from 39.2% in the previous year. With cash and deposits of ¥777.5B against long-term borrowings of ¥251.7B, the company has a substantial liquidity buffer and a conservative financial base.

Cash Flow Analysis

Although a cash flow statement was not disclosed, movements in funds can be inferred from changes in the balance sheet. Cash and deposits were ¥777.5B, down ¥28.1B from ¥805.7B in the previous year. Accounts receivable and notes receivable declined substantially from the previous year, while accounts payable and notes payable also decreased. Inventories increased by ¥24.4B, potentially indicating that inventory accumulation tied up funds. The significant decrease in income taxes payable reflects taxes paid for the previous period and is considered a temporary cash outflow factor. Overall, while the company continues to maintain substantial cash balances, the long collection cycle for accounts receivable and the increase in inventories warrant attention when assessing the quality of cash generation.

Quality of Earnings

The current period was characterized by a significant contribution from non-operating factors in addition to recurring income generated by operating activities. Non-operating income was ¥7.3B, consisting of dividends received of ¥1.4B, foreign exchange gains of ¥0.7B, and equity-method investment gains of ¥3.0B, among other items. Although this represented only approximately 0.4% of revenue and was limited in absolute scale, it made a meaningful contribution to the increase in Ordinary Income. Extraordinary income and losses consisted solely of an extraordinary loss of ¥0.3B, representing a loss on the disposal of fixed assets, while extraordinary income was minimal; accordingly, the impact of one-time factors was limited. The gap between Ordinary Income of ¥33.8B and Net Income of ¥20.6B was primarily attributable to the higher tax burden, with the effective tax rate increasing from the previous year. The earnings structure compensates for lower Operating Income through non-operating factors, and caution is therefore warranted regarding the sustainability of profit growth unless operating performance improves.

Earnings Forecast and Guidance

Progress against the full-year company plan was generally on track for Revenue at 23.8% (¥1763.6B/¥7400.0B), while Operating Income was 10.7% (¥27.8B/¥260.0B) and Ordinary Income was 12.8% (¥33.8B/¥265.0B), both substantially below the quarterly run-rate benchmark of 25%. Progress for Net Income was also limited. The company has made no revisions to either its earnings forecast or dividend forecast, and achievement of the full-year plan appears to depend on a recovery in the gross margin and progress in recording large projects during the second half of the year. The gap between revenue progress and profit progress reflects the impact of gross-margin deterioration in Q1, making the trend in profit margins in subsequent quarters the key to achieving the plan.

Shareholder Returns

The company’s annual dividend plan is ¥65, and its company-planned EPS is ¥174.99, implying a Payout Ratio of approximately 37.1%. Given the low level of interest-bearing debt and substantial cash and deposits, the company appears to have strong resilience in terms of securing funds for dividends. The company holds 269.95 thousand treasury shares, equivalent to approximately 2.9% of the 9435.0 thousand issued shares. The latest disclosure did not present any new policy regarding share repurchases, and shareholder returns remain centered on dividends.

Risk Factors

1. Structural decline in profitability: The gross margin deteriorated from the previous year to 7.7%, while the Operating Margin of the core Medical Supplies Business remained at just 0.8%. Changes in project and product mix and delays in passing on higher costs through pricing are underlying factors, raising concerns about further dilution of profitability.

2. Decline in working capital efficiency: Inventories increased by ¥24.4B from the previous year, indicating inventory accumulation. Accounts receivable and notes receivable were large at ¥1192.2B, and the length of the collection cycle may affect cash generation capacity.

3. Sustainability of the earnings mix: Growth in Ordinary Income depends to a certain extent on non-operating factors such as foreign exchange gains, equity-method investment gains, and dividends received, which are compensating for weakness at the operating level. Given the volatility of non-operating factors, caution is warranted regarding the sustainability of profit growth.

Industry Benchmark (For Reference; Company Analysis)

Industry Benchmark (trading)

Profitability and Returns

The company’s profitability metrics are below the industry median, with both its Operating Margin and Net Margin ranking toward the lower end of the industry.

Growth and Capital Efficiency

The Revenue Growth Rate exceeds the industry median, and top-line expansion is relatively strong within the industry.

※Source: Company analysis

Key Points from the Results

1. Although top-line growth continues to exceed the industry average, Operating Income has continued to decline due to gross-margin deterioration, indicating an earnings structure in which revenue growth is not readily translating into profit growth.

2. Growth in Ordinary Income and Net Income is substantially supported by non-operating factors such as foreign exchange gains and equity-method investment gains, and the data indicates that this profit growth has occurred without improvement at the operating level.

3. Revenue progress against the full-year plan is solid at 23.8%, while Operating Income progress is substantially lower at 10.7%; progress toward restoring profitability in the second half of the year will be a focus of future earnings releases.

Theoretical Share Price (Reference Value)

This is a mechanically calculated reference range based solely on publicly available data using a residual income model (Ohlson-type model with an explicit 5-year fade). It is not a forecast of the market share price or a recommendation to take any specific investment action.

Sensitivity: ¥1,660–¥1,757 at Cost of Equity ±1%; ¥1,705–¥1,711 at ω±0.1.

Notes:

• Net assets as of the end of the quarter are used (there is a time lag relative to the full-year forecast).
• Because net assets include non-controlling interests, the theoretical value may be calculated somewhat higher.

(Model used: Residual Income Model / Interest rate reference month: 2026-07 / This value does not forecast or guarantee the future share price)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings summary data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the company based on publicly disclosed earnings data. Investment decisions should be made at your own discretion and responsibility, after consulting a professional advisor where necessary.

---End of Report---

---

AI Financial Analysis

Executive Summary

FY2027 Q1 was a mixed result: revenue growth remained solid, but core operating profitability weakened and earnings growth was driven by non-operating factors. Consolidated revenue increased 8.0% year on year to ¥176.36bn. Operating income declined 5.7% to ¥2.78bn despite the higher sales base. Gross profit fell 0.7% to ¥13.64bn, indicating that revenue growth did not translate into gross-profit growth. Gross margin compressed by 70bp year on year to 7.7% from 8.4%. SG&A expenses increased 0.7% to ¥10.86bn, materially slower than revenue growth but still exceeding the decline in gross profit. Consequently, operating margin fell by 20bp to 1.6% from 1.8%. Ordinary income nevertheless rose 9.2% to ¥3.38bn, supported by non-operating income of ¥7.30bn, up from ¥5.08bn in the prior-year quarter. The swing included a ¥0.70bn foreign-exchange gain versus a ¥2.19bn foreign-exchange loss a year earlier, while equity-method earnings increased to ¥2.99bn from ¥1.44bn. Profit attributable to owners of parent rose 2.9% to ¥2.09bn, or ¥22.74 per share. The effective tax rate was relatively high at 38.8%, limiting conversion of pre-tax income into net income. The annualized ROE was 5.6%, below the usual 8% threshold for satisfactory capital efficiency. The low 1.6% EBIT margin is a material feature of the business model and leaves earnings sensitive to modest procurement, reimbursement, pricing, or product-mix changes. Receivables were ¥119.22bn and annualized DSO was 62 days, slightly above the 60-day quality-alert threshold. Liquidity is adequate, with a 137.7% current ratio, a 123.2% quick ratio, and cash of ¥77.75bn. Full-year company guidance calls for 3.0% revenue growth and 6.2% operating-income growth, requiring substantial margin recovery after a weak Q1 operating-profit start. Management has not revised either earnings or dividend guidance.

Profitability Analysis

The reported annualized DuPont ROE of 5.6% is decomposed into a 1.2% net profit margin, 1.897x asset turnover, and 2.51x financial leverage. The principal constraint on ROE is profitability rather than asset utilization: a 1.2% net margin and 1.6% EBIT margin provide limited return generation even with relatively strong turnover. Financial leverage supports shareholder returns, but it does not compensate fully for the thin operating margin. Revenue expanded 8.0%, while gross profit declined 0.7%, making gross-margin compression the largest negative earnings driver. Gross margin fell to 7.7% from 8.4%, a 70bp contraction. Operating margin declined to 1.6% from 1.8%, a 20bp contraction, as gross-profit pressure outweighed restrained SG&A growth. SG&A increased only 0.7%, substantially below revenue growth, so overhead discipline was not the principal source of the operating-income decline. The quality alert for low operating efficiency is warranted: a 1.6% EBIT margin is below the 5% reference level and makes the group vulnerable to minor changes in purchasing costs and competitive pricing. The low gross-margin alert is also structurally relevant, as the Medical Supply business has high sales volume but a low segment margin of 0.8%. Ordinary-income growth was not matched by operating-income growth because non-operating income increased and non-operating expenses declined. Equity-method earnings of ¥2.99bn represented 8.9% of profit before tax, while foreign exchange moved to a ¥0.70bn gain from a ¥2.19bn loss. These factors improved reported earnings but are less directly indicative of underlying operating-margin momentum. The tax burden was 0.623, corresponding to a 38.8% effective tax rate, while the interest burden exceeded 1.0 because net non-operating income more than offset interest expense. Interest coverage was strong at 27.84x, indicating that interest expense of ¥1.00bn is not currently a material constraint.

Growth Assessment

Revenue growth was broad-based but profit conversion varied significantly by segment. Medical Supply remained the core business by segment-profit contribution, generating revenue of ¥131.99bn, up 8.3% year on year, and segment profit of ¥10.88bn, down 7.6%. Its segment margin contracted to 0.8% from 1.0%, and this large-scale, low-margin business was the main drag on consolidated operating-income growth. Total Pack Produce revenue increased 11.9% to ¥26.66bn, while segment profit was essentially flat at ¥4.67bn; its margin declined to 1.8% from 2.0%. Life Care revenue declined 1.4% to ¥9.10bn, but segment profit increased 11.6% to ¥4.63bn, lifting its margin to 5.1% from 4.5%. Dispensing Pharmacy revenue grew 3.1% to ¥8.61bn, while segment profit declined 8.4% to ¥8.50bn and its margin compressed to 9.9% from 11.1%. The increase in unallocated costs and eliminations to a negative ¥0.86bn from negative ¥0.35bn also weighed on consolidated operating income. Full-year revenue guidance of ¥740.0bn implies Q1 progress of 23.8%, broadly in line with the standard 25% run rate. Operating-income progress was only 10.7% against the ¥26.0bn full-year target, 14.3 percentage points below the standard Q1 run rate. Ordinary-income progress was 12.8% against the ¥26.5bn forecast, also below a normal Q1 progression. Profit attributable to owners progressed 13.1% against the ¥16.0bn forecast. The gap between revenue progress and profit progress means that delivery of full-year guidance depends on a meaningful improvement in gross margin and segment-profit conversion in subsequent quarters. The forecast assumes operating income rises 6.2% for the full year despite the Q1 decline, making procurement conditions, pricing discipline, and recovery in Medical Supply and Pharmacy margins central monitoring variables.

Financial Health

Financial health is sound from a near-term liquidity perspective. Current assets of ¥257.67bn exceeded current liabilities of ¥187.19bn, producing a current ratio of 137.7%. The quick ratio was 123.2%, showing that liquidity coverage does not depend on inventory liquidation. Working capital was positive at ¥70.49bn. Cash and deposits of ¥77.75bn were 56.84 times short-term loans of ¥1.37bn, limiting short-term refinancing risk. Interest-bearing debt totaled ¥26.54bn, consisting primarily of long-term loans of ¥25.17bn. Debt represented 15.2% of capital, a conservative level relative to the 40% credit benchmark. The reported debt-to-equity ratio was 1.51x, below the 2.0x aggressive-financing warning threshold, although total liabilities were equivalent to 60.2% of assets. The maturity profile is favorable because short-term loans are minimal relative to current assets and cash. Long-term borrowings are also readily covered by cash balances. Owners' equity was ¥146.83bn and the capital adequacy ratio was 39.5%. Goodwill was ¥6.56bn, equal to only 4.4% of equity and 1.8% of assets, indicating limited balance-sheet dependence on acquired goodwill values. Intangible assets were 3.1% of assets, also within conservative M&A-risk parameters. No material goodwill movement or impairment was recognized during the quarter.

Notable B/S Changes

Total assets: -¥133.23bn (-3.5%) year on year, largely reflecting lower current assets and indicating a reduced balance-sheet footprint. Current liabilities: -¥87.29bn (-4.5%) year on year, supporting a modest improvement in the current ratio to 137.7% from approximately 138.1% despite lower current assets. Income taxes payable: -¥47.32bn (-78.3%) year on year, a significant reduction in short-term obligations that contributed to the lower current-liability balance. Treasury stock: -¥7.74bn (+15.3% in absolute carrying amount) year on year, indicating increased treasury-share holdings.

Cash Flow Quality

Dividend Sustainability

The full-year dividend forecast is ¥65.00 per share, with no revision announced. Based on forecast EPS of ¥174.99, the implied dividend payout ratio is approximately 37.1%. This is below the 60% sustainability reference level and leaves a material earnings retention buffer. Retained earnings were ¥113.33bn, providing substantial accounting capacity for distributions. Treasury stock increased to negative ¥5.82bn from negative ¥5.05bn a year earlier, consistent with a ¥0.77bn increase in the carrying amount of treasury shares. Dividend sustainability will depend principally on achievement of the full-year ¥16.0bn profit forecast and preservation of operating margins, given the low-margin profile of the core Medical Supply business.

Risk Assessment

Business risks include Margin pressure is the highest operational risk: gross margin contracted 70bp to 7.7% and EBIT margin was only 1.6%, so small changes in supplier pricing, reimbursement conditions, competitive pricing, or sales mix can have an outsized earnings impact., Medical Supply, the largest profit contributor, recorded an 8.3% revenue increase but a 7.6% segment-profit decline, with margin falling to 0.8% from 1.0%., Dispensing Pharmacy segment profit declined 8.4% despite 3.1% revenue growth, reducing margin by roughly 120bp to 9.9%., Healthcare distribution and pharmacy operations face industry-specific exposure to reimbursement-policy changes, drug-price revisions, procurement-cost inflation, and labor-cost pressure..

Financial risks include Annualized DSO was 62 days, above the 60-day quality-alert threshold. This indicates slower cash collection relative to the benchmark and requires monitoring despite the year-on-year decline in receivables., Reported debt-to-equity of 1.51x is not at an aggressive level, but the 2.51x financial-leverage component of ROE means returns retain some sensitivity to balance-sheet funding conditions., Net income is supported by non-operating items, including ¥2.99bn of equity-method earnings and a ¥0.70bn FX gain, which may be more variable than core operating profit..

Key concerns include Q1 operating-income progress of 10.7% is materially below the standard 25% run rate required to achieve the full-year operating-income forecast., The low-operating-efficiency quality alert is confirmed by the 1.6% EBIT margin; the core investment issue is restoration of gross-profit and segment margins rather than sales growth alone., The low-gross-margin quality alert is confirmed by a 7.7% gross margin, reflecting limited room to absorb cost inflation without pricing or mix improvement., The high-receivable-days quality alert is confirmed by 62 days of annualized DSO; collection discipline remains important in a high-volume distribution model..

Investment Implications

Key takeaways include Revenue momentum is positive, with consolidated sales up 8.0% and three of four segments delivering year-on-year sales growth., Core operating performance weakened, as operating income fell 5.7% and gross margin contracted 70bp., Ordinary-income growth of 9.2% was supported by improved non-operating income, including higher equity-method earnings and a favorable FX swing., The balance sheet has strong liquidity and conservative interest-bearing debt relative to cash and capital., The ¥65.00 forecast dividend implies a moderate 37.1% forecast payout ratio..

Metrics to watch include Consolidated gross margin and operating margin, Medical Supply segment margin and profit conversion, Dispensing Pharmacy segment margin, Q2 cumulative operating-income progress against the ¥26.0bn full-year forecast, Annualized DSO and receivables collection trends, Equity-method earnings and foreign-exchange gains or losses, Treasury-share movements and total shareholder-return activity.

Regarding relative positioning, The group combines high asset turnover, solid liquidity, and low direct debt burden with structurally thin margins. Its annualized 5.6% ROE is below the usual 8% capital-efficiency threshold, so relative earnings quality is most dependent on sustained gross-margin discipline and on whether non-operating gains can be replaced by stronger operating-profit growth.